Dupilumab becomes the AD standard of care (2017)
The FDA approved dupilumab, the first biologic for moderate-to-severe atopic dermatitis, after trials showed a substantial share of patients on biweekly dosing reaching clear or almost-clear skin. It quickly became the top-selling AD biologic.
Dupilumab became the default biologic for severe eczema within months of approval.
It proved the IL-4/IL-13 pathway is the main driver of type-2 inflammation in AD, reshaping the treatment market.
Zumilokibart targets the same pathway with a half-life permitting far fewer injections, the main differentiation for a late entrant.
